Comments
The European Medicines Agency (EMA) on Thursday said its human medicines committee (CHMP) has recommended the emergency use of anti-viral treatment Remdesivir in adults and adolescents with Covid-19, who require oxygen support.
The antiviral treatment by Gilead Sciences Inc has been recommended for conditional approval, making it the first Covid-19 treatment to be on track to get a green light in the region, Reuters reported.
The EMA endorsement comes weeks after a speedy review. Once it is approved by the European Commission, which usually follows CHMP recommendations, physicians will be able to prescribe the drug to patients aged 12 and above with Covid-19 induced pneumonia, the report said.
The conditional approval allows a treatment to be sold across the EU’s 27 countries for a year before all necessary data on its efficacy is available. Gilead will require to submit the final data by December, it said.
Remdesivir has already received approval for emergency use in severely-ill patients in the US, India and South Korea. Japan has given full approval to the drug, the report said.
The drug has been licensed by Cipla and Hetero in India, according to previous reports.
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.